Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Monday 01 August, 2005

XTL Biopharm Ltd

EGM Statement

XTL Biopharmaceuticals Ltd
01 August 2005


                     Extraordinary General Meeting Statement

                 Michael Weiss accepts appointment as Chairman

Rehovot, Israel, 1 August 2005 - XTL Biopharmaceuticals Ltd. ('XTLbio')
announced that at its Extraordinary General Meeting (EGM) held earlier today at
XTLbio's offices, all the resolutions proposed to the shareholders were
approved.

XTLbio also announces the appointment of Michael Weiss as Non-Executive Chairman
with immediate effect. Mr. Weiss became a Non-Executive Director of XTLbio in
November 2004 and has been Interim Chairman since March 2005. He is also
Chairman and CEO of New York-based Keryx Biopharmaceuticals, Inc.

Michael Weiss, Chairman, commented:
'We are all very excited to have this chapter in XTLbio's history behind us. The
shareholders have now spoken twice in support of the positive changes at the
Company. The new board is dedicated to serving the interests of the shareholders
and lead the Company forward. Accordingly, I am delighted to move from Interim
Chairman to Chairman and lead this new board and the new company into the
future.'

Contacts:

XTLbio
Jonathan Burgin, Chief Financial Officer           Tel: +972 8 930 4440

Notes to Editors
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. Established in 1993, XTLbio became a public company in
2000 and its ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange under the symbol XTL and
in the Tel Aviv Stock Exchange, Israel.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                 

a d v e r t i s e m e n t